New BD BACTEC(TM) FX Blood Culture System with the BD EpiCenter(TM) Operating System now Available Worldwide

    Can Facilitate Fast and Effective Clinical Decisions for Patients with
Bacterial Infections
    SPARKS, Md., Jan. 14 /CNW/ -- BD Diagnostics, a segment of BD, today
announced the worldwide launch of the BD BACTEC(TM) FX Blood Culture System to
detect bloodstream infections. This new system improves clinical
decision-making and laboratory workflow by markedly improving blood culturing
practices with real-time, remotely accessible, actionable results that can
enhance patient care.  The BD BACTEC FX System is designed to continue the
media performance excellence expected from the BD BACTEC line: from Plus and
Lytic to Peds and media for yeast, fungi or mycobacteria recovery.

    "The new BD BACTEC FX System responds to customer requests for an
efficient blood culture workflow process by reducing hands-on time and
enhancing blood culture observation both inside and outside of the
microbiology lab. The system utilizes the breadth of current media containing
our patented resin that provides unmatched recovery of pathogens from the
blood," said David Panneton, Vice President, WW Marketing, BD Diagnostics -
Diagnostic Systems. "It is the result of 40 years of blood-culturing expertise
and customer interaction, with more than 10,000 blood culture instruments
installed worldwide."

    The BD BACTEC FX System enables remote observation of blood culture data
from outside the microbiology laboratory through integration with the BD
EpiCenter(TM) Microbiology Data Management System. This innovative capability
allows clinician access to laboratory results during any shift and provides a
visible and audible alarm on the remote BD EpiCenter client or on an existing
computer monitor in a more highly occupied area of the lab. All of the
information is available 24 hours a day, seven days a week by fax, e-mail,
mobile phone text messaging or beeper to any off-site healthcare professional.
Lab personnel no longer need to interrupt evening or midnight workflow to
repeatedly check with the microbiology department for positive blood cultures.

    By providing data access at the same remote computer that provides the
alarm, the system facilitates immediate decision-making.  With the information
provided, clinicians can initiate appropriate next steps to diagnose the
infection, such as performing a Gram stain, subculture, or direct
identification of Staphylococcus aureus or methicillin-resistant
Staphylococcus aureus with the BD GeneOhm(TM) StaphSR assay.  These steps
could lead to earlier, appropriate clinical decisions for effective
antimicrobial interventions.

    Multi-source data integration provides comprehensive reporting
capabilities across all BD BACTEC FX and BD BACTEC(TM) 9000 blood culture
instruments, eliminating the need for manual report consolidation on more than
five instruments. Data from numerous BD BACTEC FX instruments can be
consolidated into one reporting system with the BD EpiCenter system. When
combined with the BD Phoenix(TM) Automated Microbiology System, BD EpiCenter
will provide rapid and synchronized blood culture, bacterial identification
and susceptibility information flow to the laboratorian and physician,
enhancing patient care.

    The BD BACTEC FX System maintains the proven high performance and
instrument reliability of its predecessor, the BD BACTEC 9000 System. It
retains the fluorescent technology that represents excellence in blood culture
isolate recovery, along with exceptional instrument and media performance. The
BD BACTEC FX System has a compact and versatile system design.  It offers a
200-vial benchtop unit or a full 400-vial stack that includes an embedded,
centralized computer -- all in a highly compact 24-inch linear space which
represents the smallest and most reliable design available.

    Among the first BD BACTEC FX global owners are:
    --  King Faisal Specialist Hospital & Research Center, Riyadh, Kingdom of
        Saudi Arabia
    --  Vancouver General Hospital in Vancouver, British Columbia
    --  The Hospital for Sick Children in Toronto, Ontario
    --  County Durham and Darlington NHS Foundation Trust in Darlington,
    --  Poole Hospital in Dorset, United Kingdom.

    Additionally, BD has seen successful BD BACTEC FX implementation in the
United States, Australia and Europe.

    For more information, visit:

    About BD

    BD is a leading global medical technology company that develops,
manufactures and sells medical devices, instrument systems and reagents. The
Company is dedicated to improving people's health throughout the world. BD is
focused on improving drug therapy, enhancing the quality and speed of
diagnosing infectious diseases, and cancers, and advancing research, discovery
and production of new drugs and vaccines. The Company's capabilities are
instrumental in combating many of the world's most pressing diseases. Founded
in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs
approximately 28,000 people in approximately 50 countries throughout the
world. The Company serves healthcare institutions, life science researchers,
clinical laboratories, the pharmaceutical industry and the general public. For
more information, please visit


For further information:

For further information: Barbara Kalavik, Public Relations,
+1-201-847-4209, Web Site:       

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890